News

Genentech and AC Immune partner again
Enlarge image

BusinessSwitzerland

Genentech and AC Immune partner again

19.06.2012 - Six years after their first alliance, Swiss AC Immune SA partners again with US-American Genentech Inc.

Basel/Lausanne – The subject of the new cooperation remained the same: fighting Alzheimer's disease. Therefore the Roche subsidiary has now in-licensed a second generation of AC Immune's antibodies - this time directed to bind the Tau protein. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and research, development and commercialisation milestone payments totalling more than CHF400m. Additionally, AC Immune could pocket royalties on net sales resulting from the collaboration – if the product is approved.

Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. The pharma will have global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of antibodies resulting from the collaboration. Scientifically, both partners are building on the first alliance as the new Tau antibodies are thought to flank Crenezumab, an antibody in phase II resulting from the first cooperation that binds amyloid-beta-plaques (abeta).

By blocking Tau- fibrillation and destroying abeta aggregates, AC Immune attacks the two crucial steps in Alzheimer development. AC Immune has raised CHF64m since its foundation in 2003. Financiers are business angels from Switzerland and prominent biotech supporters like Dietmar Hopp, the founder of the German business software maker SAP. Beside the out- licensed antibody projects, AC immune develops a proprietary small molecule pipeline

http://www.european-biotechnology-news.com/news/news/2012-02/genentech-and-ac-immune-partner-again.html

ResearchUK

30.01.2015 AstraZeneca has joined forces with four research collaborations to use breakthrough CRISPR gene editing technology across its drug discovery platform.

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%
  • ADDEX3.28 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.84 EUR0.00%
  • ACTELION100.80 CHF0.00%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2544.8%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.1%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 31.01.2015